A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This is a randomized (patients will be assigned by chance to study treatments), double-blind
(patients and study personnel will not know the identity of study treatments), placebo (an
inactive substance that is compared with a drug to test whether the drug has a real effect in
a clinical trial)-controlled study to determine the benefits and risks of combining ibrutinib
with bendamustine and rituximab (BR) in patients with relapsed or refractory CLL/SLL
following at least 1 line of prior systemic therapy. Approximately 580 patients will be
randomized in a 1:1 ratio to either treatment arm A (placebo) or treatment arm B (ibrutinib
420 mg).

Study medication will be administered orally once daily on a continuous schedule. All
patients will receive BR as the background therapy plus either ibrutinib or placebo for a
maximum of 6 cycles, after which treatment with ibrutinib or placebo will continue until
disease progression or unacceptable toxicity.

A treatment cycle will be defined as 28 days. The study will include a screening phase, a
treatment phase, and a follow-up phase. Study end is defined as when either 80% of the
patients have died or 5 years after the last patient is randomized into the study, whichever
occurs first.

Patients in treatment arm A (placebo) who complete the treatment phase, with disease
progression or (after interim analysis) meet International Workshop on Chronic Lymphocytic
Leukemia (IWCLL) criteria for treatment, may crossover to ibrutinib treatment (as in
treatment arm B), at the investigators discretion. This open-label, next-line treatment with
ibrutinib will continue until disease progression, unacceptable toxicity, withdrawal from
study, or until the study end, whichever occurs earlier. One interim analysis is planned for
the study. Efficacy evaluations will include computed tomography scans, laboratory testing,
focused physical examinations, bone marrow biopsy and aspirate, and assessment of
patient-reported outcomes. In both treatment arms, samples for the development of a
population-based pharmacokinetic (PK; study of what the body does to a drug) approach will be
collected. Safety will be assessed throughout the study.

Inclusion Criteria:

- Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
that meets protocol-defined criteria

- Active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic
Leukemia 2008 criteria for requiring treatment

- Measurable nodal disease by computed tomography

- Relapsed or refractory CLL or SLL following at least 1 prior line of systemic therapy
consisting of at least 2 cycles of a chemotherapy-containing regimen

- Eastern Cooperative Oncology Group Performance Status score of 0 or 1

- Hematology and biochemical values within protocol-defined limits

- Agrees to protocol-defined use of effective contraception

- Women of childbearing potential must have negative blood or urine pregnancy test at
screening

Exclusion Criteria:

- Recent therapeutic interventions within 3 (chemotherapy/radiotherapy) to 10 weeks
(immunotherapy)

- Prior treatment with ibrutinib or other Bruton's tyrosine kinase inhibitors or prior
randomization in any other clinical study evaluating ibrutinib

- The presence of deletion of the short arm of chromosome 17

- Patients previously treated with a bendamustine-containing regimen who did not achieve
a response or who relapsed and required treatment within 24 months of treatment with
that regimen

- Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant

- Received a hematopoietic stem cell transplant

- Known central nervous system leukemia/lymphoma or Richter's transformation

- Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia

- Chronic use of corticosteroids

- History of prior malignancy, except: malignancy treated with curative intent and with
no known active disease present for >=3 years before randomization; adequately treated
non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately
treated cervical carcinoma in situ without evidence of disease

- History of stroke or intracranial hemorrhage within 6 months prior to randomization;
or clinically significant cardiovascular disease

- Requires anticoagulation with warfarin or equivalent vitamin K antagonists or
treatment with strong CYP3A4/5 inhibitors

- Known history of human immunodeficiency virus or hepatitis C, or active infection with
hepatitis B or C

- Any uncontrolled active systemic infection or any life-threatening illness, medical
condition, or organ system dysfunction which, in the investigator's opinion, could
compromise the patient's safety, interfere with the absorption or metabolism of
ibrutinib capsules, or put the study outcomes at undue risk

- A woman who is pregnant or breast feeding, or a man who plans to father a child while
enrolled in this study or within 3 months after the last dose of study drug